BioSyent

BioSyent FCF/Debt

The Free Cash Flow to Debt Ratio of BioSyent (RX.V) as of Oct 6, 2026 is 384.87 %. In the previous year, Free Cash Flow to Debt Ratio was 258.10 % — a change of 49.12% (higher).

FCF/Debt

384.87 %

YoY

49.12%

Last updated:

Free Cash Flow to Debt Ratio of BioSyent is 2026 384.87 % . Free Cash Flow to Debt Ratio of BioSyent was 2025 258.10 % . It decreases by 49.12% higher compared to the previous year.

The BioSyent FCF/Debt history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

FCF/Debt
Date
FCF/Debt
Jan 1, 2019
217.85 CAD
Jan 1, 2020
393.24 CAD
Jan 1, 2021
294.28 CAD
Jan 1, 2022
317.50 CAD
Jan 1, 2023
258.10 CAD
Jan 1, 2024
384.87 CAD
The BioSyent FCF/Debt history
YEARFCF/DebtYoY
384.87 %+49.12%
258.10 %-18.71%
317.50 %+7.89%
294.28 %-25.16%
393.24 %+80.51%
217.85 %—
Access this data via the Eulerpool API

BioSyent Stock analysis

What does BioSyent do? Biosyent Inc is a Canadian pharmaceutical company founded in 2004. The company's headquarters are located in Mississauga, Ontario. Biosyent is listed on the Toronto Stock Exchange and has a market capitalization of approximately 140 million Canadian dollars. The company's business model is based on acquiring domestic pharmaceutical and nutraceutical products and marketing them in Canada. Biosyent operates in two main divisions: Pharma and Nutraceuticals. The Pharma division includes products such as RepaGyn, a vaginal gel for treating dryness and irritation during menopause, as well as the antiemetic Setofilm/Tablets for the prevention and treatment of nausea and vomiting. The Nutraceutical division includes products such as FeraMAX, a supplement that increases iron in the diet and helps prevent the development of anemia. Biosyent also offers vitamin-rich dietary supplements such as Aerobic Oxygen and Calm Biotic, targeting health-conscious customers. Another important area of Biosyent is Hospital Specialty Pharmaceuticals, targeting hospitals and healthcare facilities. This includes products like Cysview and Cysview Kit, used to detect non-muscle invasive bladder cancer and improve fluorescence during cystoscopy. Biosyent also offers infusion sets designed for intravenous medication administration. Overall, Biosyent has more than 20 products in various categories including women's and men's health, ophthalmology, immunology, and oncology. Over the years, Biosyent Inc has received various awards for its products and business practices. In 2012, the company received the Bio-Wellness Award for its flagship product, RepaGyn. While Biosyent has ambitions to expand its presence in international markets, the company remains primarily focused on the Canadian market. Biosyent relies mainly on a low-cost marketing strategy that aims to directly target patients in order to market its products in a simple way. Overall, Biosyent has a strong market position in Canada and a portfolio of well-established products. The company has a successful history and appears ready for the future with a strong pipeline and a growing presence in the Canadian market. BioSyent is one of the most popular companies on Eulerpool.

Frequently Asked Questions about BioSyent stock

Free Cash Flow to Debt Ratio of BioSyent is 384.87 % in 2026.

Free Cash Flow to Debt Ratio of BioSyent changed from 258.10 % to 384.87 %, representing a 49.12% change. The value is higher than the previous year.

On Eulerpool you can find the complete historical development of Free Cash Flow to Debt Ratio BioSyent since 2006 – with annual values, charts, and detailed analysis.

FCF/Debt measures the percentage of total debt that could be repaid from free cash flow. It is a stricter measure than OCF/Debt as it accounts for capital expenditures.

A 'good' varies by industry and company stage. On Eulerpool, you can compare Free Cash Flow to Debt Ratio's BioSyent with sector peers and the industry average to assess whether it is attractive.

Access this data via the Eulerpool API

Leverage — BioSyent

All Key Metrics — BioSyent